This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Utilizing human cerebral organoids to model breast cancer brain metastasis in culture
Breast Cancer Research Open Access 01 July 2024
-
The tumour microenvironment, treatment resistance and recurrence in glioblastoma
Journal of Translational Medicine Open Access 06 June 2024
-
Nose-to-brain selective drug delivery to glioma via ferritin-based nanovectors reduces tumor growth and improves survival rate
Cell Death & Disease Open Access 13 April 2024
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev 2001; 15: 1311–1333.
He H, Yao M, Zhang W, Tao B, Liu F, Li S et al. MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment. Cell Mol Immunol 2016; 13: 658–668.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et alBRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–2516.
Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005; 2: 119–130.
Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 2011; 19: 305–316.
Liu C, Sage JC, Miller MR, Verhaak RG, Hippenmeyer S, Vogel H et al. Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell 2011; 146: 209–221.
Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E et al. Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell 2015; 28: 429–440.
Ghazi SO, Stark M, Zhao Z, Mobley BC, Munden A, Hover Let al.Cell of origin determines tumor phenotype in an oncogenic Ras/p53 knockout transgenic model of high-grade glioma. J Neuropathol Exp Neurol 2012; 71: 729–740.
Zong H. Generation and applications of MADM-based mouse genetic mosaic system. Methods Mol Biol 2014; 1194: 187–201.
Zong H, Espinosa JS, Su HH, Muzumdar MD, Luo L. Mosaic analysis with double markers in mice. Cell 2005; 121: 479–492.
Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol 2014; 12: 207–218.
Lan X, Jörg DJ, Cavalli FMG, Richards LM, Nguyen LV, Vanner RJ et al. Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature 2017; 549: 227–232.
Ledur PF, Liu C, He H, Harris AR, Minussi DC, Zhou HY et al. Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells. Neuro-Oncology 2016; 18: 1413–1424.
Sreedharan S, Maturi NP, Xie Y, Sundström A, Jarvius M, Libard S et al. Mouse models of pediatric supratentorial high-grade glioma reveal how cell-of-origin influences tumor development and phenotype. Cancer Res 2017; 77: 802–812.
Jiang Y, Marinescu VD, Xie Y, Jarvius M, Maturi NP, Haglund C et al. Glioblastoma cell malignancy and drug sensitivity are affected by the cell of origin. Cell Rep 2017; 19: 1080–1081.
Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ et al. Long-term Survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clin Cancer Res 2017; 23: 1898–1909.
Acknowledgements
This work was supported by NSFC81302187, CWS14C063 and SIMM1705KF-10 (State Key Laboratory of Drug Research).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Yao, M., Li, S., Wu, X. et al. Cellular origin of glioblastoma and its implication in precision therapy. Cell Mol Immunol 15, 737–739 (2018). https://doi.org/10.1038/cmi.2017.159
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cmi.2017.159
Keywords
This article is cited by
-
The tumour microenvironment, treatment resistance and recurrence in glioblastoma
Journal of Translational Medicine (2024)
-
Utilizing human cerebral organoids to model breast cancer brain metastasis in culture
Breast Cancer Research (2024)
-
Nose-to-brain selective drug delivery to glioma via ferritin-based nanovectors reduces tumor growth and improves survival rate
Cell Death & Disease (2024)
-
Protective effects of silymarin in glioblastoma cancer cells through redox system regulation
Molecular Biology Reports (2024)
-
Rewiring of the promoter-enhancer interactome and regulatory landscape in glioblastoma orchestrates gene expression underlying neurogliomal synaptic communication
Nature Communications (2023)